Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) on Monday, plunged -6.23% from the previous trading day, before settling in for the closing price of $0.48. Within the past 52 weeks, ADAP’s price has moved between $0.46 and $2.05.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 193.13% over the last five years. The company achieved an average annual earnings per share of 71.06%. With a float of $226.47 million, this company’s outstanding shares have now reached $255.70 million.
The firm has a total of 449 workers. Let’s measure their productivity. In terms of profitability, gross margin is 95.26%, operating margin of -28.14%, and the pretax margin is -28.42%.
Adaptimmune Therapeutics Plc ADR (ADAP) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Adaptimmune Therapeutics Plc ADR is 11.49%, while institutional ownership is 37.31%. The most recent insider transaction that took place on Jan 17 ’25, was worth 3,243. In this transaction Chief Medical Officer of this company sold 5,584 shares at a rate of $0.58, taking the stock ownership to the 7,510 shares. Before that another transaction happened on Jan 17 ’25, when Company’s Chief Patient Supply Officer sold 5,584 for $0.58, making the entire transaction worth $3,243. This insider now owns 7,510 shares in total.
Adaptimmune Therapeutics Plc ADR (ADAP) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 71.06% per share during the next fiscal year.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Trading Performance Indicators
Adaptimmune Therapeutics Plc ADR (ADAP) is currently performing well based on its current performance indicators. A quick ratio of 3.82 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.66.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.21, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach -0.08 in one year’s time.
Technical Analysis of Adaptimmune Therapeutics Plc ADR (ADAP)
Analysing the last 5-days average volume posted by the [Adaptimmune Therapeutics Plc ADR, ADAP], we can find that recorded value of 1.33 million was better than the volume posted last year of 1.1 million. As of the previous 9 days, the stock’s Stochastic %D was 11.62%. Additionally, its Average True Range was 0.05.
During the past 100 days, Adaptimmune Therapeutics Plc ADR’s (ADAP) raw stochastic average was set at 0.97%, which indicates a significant decrease from 2.53% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 53.68% in the past 14 days, which was lower than the 71.85% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5756, while its 200-day Moving Average is $0.8603. Now, the first resistance to watch is $0.4775. This is followed by the second major resistance level at $0.5049. The third major resistance level sits at $0.5208. If the price goes on to break the first support level at $0.4342, it is likely to go to the next support level at $0.4183. Should the price break the second support level, the third support level stands at $0.3909.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Key Stats
Market capitalization of the company is 115.17 million based on 255,883K outstanding shares. Right now, sales total 60,280 K and income totals -113,870 K. The company made 40,900 K in profit during its latest quarter, and -17,620 K in sales during its previous quarter.
